2. Search Result
Search Result
Results for "

severe asthma

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

1

Peptides

9

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99366A
    Tezepelumab (anti-TSLP)

    AMG 157 (anti-TSLP); MEDI 19929 (anti-TSLP); Tezepelumab-ekko (anti-TSLP)

    		 Interleukin Related Inflammation/Immunology
    Tezepelumab (anti-TSLP) is human monoclonal antibody (IgG2λ) that binds specifically to TSLP, blocking it from interacting with its heterodimeric receptor. Tezepelumab can be used for the research of severe, uncontrolled asthma .
    Tezepelumab (anti-TSLP)
  • HY-P9945
    Mepolizumab

    SB 240563

    		 Interleukin Related Cardiovascular Disease Inflammation/Immunology
    Mepolizumab (SB 240563) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
    Mepolizumab
  • HY-P9945A
    Mepolizumab (anti-IL5)

    		Interleukin Related Inflammation/Immunology
    Mepolizumab (anti-IL5) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
    Mepolizumab (anti-IL5)
  • HY-P9923A
    Benralizumab (anti-IL5RA )
    1 Publications Verification

    MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA )

    		 Interleukin Related Apoptosis Inflammation/Immunology
    Benralizumab (anti-IL5RA ) (MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA)) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma study .
    Benralizumab (anti-IL5RA )
  • HY-Y0912
    HBTU

    N-HBTU

    		 Biochemical Assay Reagents Inflammation/Immunology
    HBTU (N-HBTU) is a guanidinium-based peptide coupling reagent and immunological sensitizer. HBTU can be used in combination with bases such as DIPEA (HY-130142) to complete coupling reactions, with HOBt and TMU as by-products. HBTU is a standard reagent in automated solid-phase peptide synthesis, particularly for the Fmoc/tBu strategy, which effectively promotes coupling steps, but it is not suitable for sterically hindered amino acids or dipeptide derivatives. HBTU can induce rhinitis, dermatitis, bronchial asthma and severe allergic reactions. HBTU can be used to study the pathogenesis of allergic reactions, occupational rhinitis, allergic contact dermatitis and bronchial asthma .
    HBTU
  • HY-P990735
    Donzakimig

    		Interleukin Related Inflammation/Immunology
    Donzakimig is a trispecific anti-IL-13/IL-22/HSA antibody. Donzakimig adopts a Fab-scFv-scFv structural format (without an Fc region), in which the Fab domain is linked to the scFv domains via a S (G4S)2 linker. Donzakimig binds to and inhibits the activities of IL-13 and IL-22, thereby blocking the signal transduction of these two cytokines. Donzakimig can extend its serum half-life by binding to human serum albumin, enhancing its in vivo stability and achieving long-acting efficacy. Donzakimig can be used in research on moderate-to-severe atopic dermatitis, moderate-to-severe asthma (especially eosinophilic type), psoriasis, inflammatory bowel disease, and other conditions .
    Donzakimig
  • HY-P990933
    Ocankitug

    CM-326

    		 Interleukin Related Inflammation/Immunology
    Ocankitug (CM-326) is a humanized IgG1κ antibody targeting thymic stromal lymphopoietin (TSLP). It can be used for research on type 2 inflammatory respiratory diseases, including moderate to severe asthma, chronic sinusitis with nasal polyps, etc.
    Ocankitug
  • HY-P9923
    Benralizumab
    1 Publications Verification

    MEDI-563; BIW-8405; KHK4563

    		 Interleukin Related Apoptosis Inflammation/Immunology Cancer
    Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma .
    Benralizumab
  • HY-P4846
    Ac-Pro-Gly-Pro-OH
    2 Publications Verification

    		 CXCR Apoptosis IFNAR TNF Receptor Interleukin Related Infection Inflammation/Immunology
    Ac-Pro-Gly-Pro-OH is an endogenous degradation product of extracellular collagen and acts as a CXCR2 agonist . Ac-Pro-Gly-Pro-OH exerts bactericidal activity by generating hydrogen peroxide, inhibits pulmonary inflammation, and reduces immune cell apoptosis (apoptosis). Ac-Pro-Gly-Pro-OH promotes the production of IFN-γ and inhibits the production of TNF-α and IL-6 in leukocytes. Ac-Pro-Gly-Pro-OH increases the survival rate of mice in sepsis models, enhances the bactericidal activity of neutrophils, acts as a neutrophil chemoattractant, induces neutrophil polarization, and regulates inflammatory and repair processes. Ac-Pro-Gly-Pro-OH induces chronic inflammation and tissue remodeling through sustained action. Ac-Pro-Gly-Pro-OH is released via alkaline hydrolysis of corneal proteins in alkali-injured eyes, thereby driving the early infiltration of neutrophils into the cornea. Ac-Pro-Gly-Pro-OH is applicable to research related to sepsis, chronic obstructive pulmonary disease, cystic fibrosis, bronchiolitis obliterans syndrome, severe asthma, idiopathic pulmonary fibrosis, and corneal ulcer .
    Ac-Pro-Gly-Pro-OH
  • HY-17457
    Levalbuterol hemitartrate

    Levosalbutamol hemitartrate

    		 Adrenergic Receptor PI3K Inflammation/Immunology
    Levalbuterol (Levosalbutamol) hemitartrate is a β2-adrenergic receptor agonist and PI3K inhibitor. Levalbuterol hemitartrate inhibits PI3K activity, reduces NF-κB and Rb protein expression, activates the cAMP/PKA pathway, and stimulates cAMP release. Levalbuterol hemitartrate relaxes airway smooth muscle, reduces intracellular calcium levels, and inhibits spasmogen-induced contractions. Levalbuterol hemitartrate can be used for the research of moderate-to-severe asthma .
    Levalbuterol hemitartrate
  • HY-P991651
    MEDI4212

    		Fc Receptor (FcR) Inflammation/Immunology
    MEDI4212 is a humanized IgG1λ monoclonal antibody inhibitor targeting IgE. MEDI4212 potently inhibits human IgE-mediated functional responses through its receptor FcεRI, such as calcium signaling, β-hexosaminidase release and phagocytosis. MEDI4212 prevents the binding of IgE to CD23 with an IC50 of 8 nM. MEDI4212 can be used severe asthma research .
    MEDI4212
  • HY-14915
    Bedoradrine

    		Adrenergic Receptor Endocrinology
    Bedoradrine is a highly selective β2-adrenergic agonist with activity in suppressing asthma and chronic obstructive pulmonary disease (COPD). Bedoradrine is administered by intravenous infusion and is specifically indicated for the suppression of acute asthma attacks. Bedoradrine has shown good safety and preliminary efficacy in clinical trials, especially in patients with stable moderate to severe asthma. The results of Bedoradrine studies have shown that it can provide clinical benefits without increasing clinical risks, especially for patients who are unable to use inhalation or nebulization suppression .
    Bedoradrine
  • HY-144075
    JAK-IN-19

    		JAK Inflammation/Immunology
    JAK-IN-19 is a potent JAK inhibitor (PBMC IFNγ pIC50=7.2 and HLF Eotaxin pIC50=7.7). JAK-IN-19 has good retentive properties in the lung via mitigating being metabolized by Aldehyde Oxidase (AO), with diminished VEGFR2 selectivity (VEGFR2 pIC50=7.0, Aurora B pIC50=5.8) .
    JAK-IN-19
  • HY-156196
    BI 894416

    		Syk Inflammation/Immunology
    BI 894416 is a spleen tyrosine kinase (SYK) inhibitor. BI 894416 has a deuterium-labeled derivative that can be used as an internal standard for bioanalytical studies. BI 894416 is applicable to the research of severe asthma .
    BI 894416
  • HY-P992447
    QX008N

    		Interleukin Related Inflammation/Immunology
    QX008N is a humanized IgG1 monoclonal antibody and also a TSLP inhibitor with a KD value of 0.0175 nM. QX008N blocks TSLP-induced signaling pathways by inhibiting the interaction of TSLP-TSLPR-IL-7Rα. QX008N reduces eosinophil and IgE levels, improves pulmonary function, blocks TSLP-induced inflammation, and enhances the inhibitory effect on inflammatory mediators when administered in combination with anti-IL-4R antibodies. QX008N is applicable to relevant research on asthma .
    QX008N

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: